SCHEDULE: Acorn Bioventures Discloses 6.2% Stake in Y-mAbs

Acorn Bioventures and related entities, including Anders Hove, have disclosed a combined 6.2% beneficial ownership stake in Y-mAbs Therapeutics, Inc.

Summary

• Amendment No. 3 to Schedule 13G has been filed by Acorn Bioventures, L.P., Acorn Bioventures 2, L.P., their general partners Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, and individual Anders Hove.
• Beneficial ownership in Y-mAbs Therapeutics, Inc. common stock is reported.
• Acorn Bioventures, L.P. beneficially owns 1,175,686 shares, representing 2.6% of the class.
• Acorn Bioventures 2, L.P. beneficially owns 1,620,611 shares, representing 3.6% of the class.
• Anders Hove, as Manager of the general partners, is deemed to beneficially own an aggregate of 2,796,297 shares, representing 6.2% of the class.
• Percentages are calculated based on 45,438,420 shares of Common Stock outstanding as of August 4, 2025, as reported in Y-mAbs' Form 10-Q for the quarter ended June 30, 2025.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership by an investment group. It does not contain operational or financial performance data to indicate a positive or negative sentiment, but rather confirms a significant existing stake.

Positives

• This disclosure primarily details beneficial ownership and does not contain specific positive operational or financial updates for Y-mAbs Therapeutics, Inc.

Negatives

• This disclosure primarily details beneficial ownership and does not contain specific negative operational or financial updates for Y-mAbs Therapeutics, Inc.

Risks

• No specific operational or financial risks of Y-mAbs Therapeutics, Inc. are detailed in this beneficial ownership disclosure.

Future Outlook

NA

Industry Context

This is a standard disclosure for institutional investors acquiring significant stakes in publicly traded companies, common in the biotechnology and pharmaceutical sectors where specialized funds like Acorn Bioventures invest in therapeutic companies.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.
• Company Management: Awareness of a significant shareholder group, potentially influencing strategic decisions or corporate governance discussions, especially given the certification regarding non-control intent 'other than activities solely in connection with a nomination under Rule 240.14a-11'.

Key Dates

Keywords

Y-mAbs Therapeutics, YMAB, Schedule 13G, Beneficial Ownership, Institutional Investor, Acorn Bioventures, Anders Hove, Biotechnology, Pharmaceuticals, SEC Filing